Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
NCT03486067
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
183
Enrollment
INDUSTRY
Sponsor class
Stopped
Business objectives have changed
Conditions
Multiple Myeloma
Interventions
DRUG:
CC-93269
Sponsor
Celgene